Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Treatment Regimens for Mifegyne and Cytotec

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2010 by Western Galilee Hospital-Nahariya.
Recruitment status was:  Recruiting
Information provided by:
Western Galilee Hospital-Nahariya Identifier:
First received: June 12, 2009
Last updated: May 24, 2011
Last verified: November 2010
The purpose of this study is to test two regimens of mifegyne and cytotec for medical abortion. The investigators hypothesize that administration of both medications during one hospital visit will not compromise effectiveness.

Condition Intervention Phase
Medical Abortion
Drug: mifegyne and cytotec
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Comparison of the Effectiveness of Abortive Measures From the Administration of Mifegyne and Cytotec at One and Two Visits

Resource links provided by NLM:

Further study details as provided by Western Galilee Hospital-Nahariya:

Primary Outcome Measures:
  • percentage of complete abortion [ Time Frame: one month ]

Estimated Enrollment: 200
Study Start Date: June 2009
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: one-visit Drug: mifegyne and cytotec
One day dosage versus two days dosage
Other Name: Comparison of one day dosing to two days dosing
Active Comparator: two-visit Drug: mifegyne and cytotec
One day dosage versus two days dosage
Other Name: Comparison of one day dosing to two days dosing


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • above age 18,
  • for whom Mifegyne and cytotec are indicated.

Exclusion Criteria:

  • inflammation of oral cavity.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00920465

Western Galilee Hospital- Nahariya Recruiting
Nahariya, Israel, 22100
Contact: Renee Tendler, MD   
Sponsors and Collaborators
Western Galilee Hospital-Nahariya
  More Information

Responsible Party: Dr. Renee Tendler, Western Galilee Hospital-Nahariya Identifier: NCT00920465     History of Changes
Other Study ID Numbers: 4-10-2007
Study First Received: June 12, 2009
Last Updated: May 24, 2011

Additional relevant MeSH terms:
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Abortifacient Agents, Steroidal
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents processed this record on May 25, 2017